Praxis Precision Medicines Inc (PRAX)

Apr 8, 2025, 8:00 AM EDT - 17 days ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 3, 2025, 5:00 PM EDT - 22 days ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Apr 3, 2025, 4:00 PM EDT - 22 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2025, 11:03 PM EST - 7 weeks ago

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Feb 28, 2025, 8:00 AM EST - 2 months ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 3, 2025, 5:00 PM EST - 2 months ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Jan 12, 2025, 9:00 PM EST - 3 months ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dec 18, 2024, 8:00 AM EST - 4 months ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 5 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB STOK WGS

Dec 3, 2024, 8:00 AM EST - 5 months ago

Praxis Precision Medicines to Present at Upcoming December Investor Conferences

Nov 6, 2024, 5:00 PM EST - 6 months ago

Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences

Nov 6, 2024, 11:56 AM EST - 6 months ago

Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:30 AM EST - 6 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:00 AM EDT - 6 months ago

Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024

Sep 4, 2024, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Sep 3, 2024, 7:30 AM EDT - 8 months ago

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Sep 2, 2024, 5:00 PM EDT - 8 months ago

Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024

Aug 14, 2024, 3:14 PM EDT - 9 months ago

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Aug 13, 2024, 2:47 PM EDT - 9 months ago

Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript

Aug 5, 2024, 4:01 PM EDT - 9 months ago

Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024

May 17, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming Investor Conferences

May 13, 2024, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 10, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

Mar 28, 2024, 12:20 AM EDT - 1 year ago

Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Mar 26, 2024, 1:34 PM EDT - 1 year ago

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Host PRAX-628 Program Update

Mar 5, 2024, 7:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 1, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference

Jan 11, 2024, 7:30 AM EST - 1 year ago

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Nov 28, 2023, 7:00 AM EST - 1 year ago

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Nov 21, 2023, 4:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 16, 2023, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Nov 7, 2023, 7:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Oct 2, 2023, 1:17 PM EDT - 1 year ago

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Sep 27, 2023, 4:15 PM EDT - 1 year ago

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

Aug 28, 2023, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

Aug 9, 2023, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study

Aug 3, 2023, 4:12 PM EDT - 1 year ago

Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference

Jul 24, 2023, 7:01 PM EDT - 1 year ago

Praxis Precision Medicines: Long List Of Failures And Mixed Data

Jun 22, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

Jun 15, 2023, 11:58 PM EDT - 2 years ago

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

Jun 2, 2023, 9:00 AM EDT - 2 years ago

Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference

May 11, 2023, 7:30 AM EDT - 2 years ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023, 6:55 AM EDT - 2 years ago

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile